Endostatin and Oxaliplatin-Based Chemoradiotherapy for Inoperable Esophageal Squamous Cell Carcinoma: Results of a Phase II Study

Wenxin Li, Peng Chen, Ni Zhang, Tao Song, Shixiu Wu, Wenxin Li, Peng Chen, Ni Zhang, Tao Song, Shixiu Wu

Abstract

Lessons learned: Definitive concurrent chemoradiotherapy based on oxaliplatin and endostatin was effective with the objective response rate exceeding 80%, and the treatment-related toxicities were acceptable.The treatment compliance of the current combination was much higher, without significant reduction in survival outcomes, than historical reports.

Background: This phase II trial aimed at assessing the efficiency and safety of definitive concurrent chemoradiotherapy (dCRT) using oxaliplatin (OHP) and endostatin in patients with inoperable esophageal squamous cell carcinoma (ESCC).

Methods: Radiotherapy was delivered with a daily fraction of 2.0 Gy to a total dose of 60.0 Gy over 6 weeks. Endostatin and OHP were both intravenously administered at doses of 7.5 mg/m2 daily for 2 weeks and 135 mg/m2 on day 1, respectively, every 3 weeks. The primary endpoint was the objective response rate (ORR).

Results: The analysis included 37 patients. The median age was 63 years (range: 49-71 years), and all patients were stage III-IVA. Of these patients, 97.3% (36/37) completed the dCRT course with an ORR of 83.8%, including 10 (27.0%) patients with complete response and 21 (56.8%) patients with partial response. The median overall survival (OS) time was 18.5 months (95% confidence interval [CI]: 10.6-26.4) with a 2-year OS rate of 39.6% (95% CI: 0.202-0.590). The median progression-free survival (PFS) time was 11.5 months (95% CI: 7.6-15.4) with a 2-year PFS rate of 20.2% (95% CI: 0.049-0.355). Grade 3 toxicities included esophagitis (five patients) and leukocytopenia (three patients). Grade 4 leukopenia was observed in one patient. Late toxicity was infrequent, and no treatment-related death occurred. Posttreatment dysphagia scores were significantly improved when compared with baseline (p < .001).

Conclusion: dCRT based on OHP and endostatin resulted in high treatment compliance with manageable toxicities. This combination resulted in encouraging ORR without compromising survival outcomes. It should be validated in future clinical studies.

Trial registration: ClinicalTrials.gov NCT02745561.

© AlphaMed Press; the data published online to support this summary are the property of the authors.

Figures

Figure 1.
Figure 1.
Waterfall plot of responses to definitive concurrent chemoradiotherapy.
Figure 2.
Figure 2.
Kaplan‐Meier curves of OS and PFS. Abbreviations: OS, overall survival; PFS, progression‐free survival.
Figure 3.
Figure 3.
Distribution of dysphagia score at baseline and after dCRT. Abbreviation: dCRT, definitive concurrent chemoradiotherapy.

References

    1. Li G, Hu W, Wang J et al. Phase ii study of concurrent chemoradiation in combination with erlotinib for locally advanced esophageal carcinoma. Int J Radiat Oncol Biol Phys 2010;78:1407–1412.
    1. Song T, Zhang X, Fang M et al. Long‐term results of definitive concurrent chemoradiotherapy using paclitaxel plus oxaliplatin in unresectable locally advanced esophageal cancer: A prospective phase ii trial. Cancer Med 2016;5:3371–3377.
    1. Cooper JS, Guo MD, Herskovic A et al. Chemoradiotherapy of locally advanced esophageal cancer: Long‐term follow‐up of a prospective randomized trial (RTOG 85‐01). Radiation Therapy Oncology Group. JAMA 1999;281:1623–1627.
    1. Suntharalingam M, Winter K, Ilson D et al. Effect of the addition of cetuximab to paclitaxel, cisplatin, and radiation therapy for patients with esophageal cancer: The NRG Oncology RTOG 0436 phase 3 randomized clinical trial. JAMA Oncol 2017;3:1520–1528.
    1. Crosby T, Hurt CN, Falk S et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): A multicentre, phase 2/3 randomised trial. Lancet Oncol 2013;14:627–637.
    1. Bendell JC, Meluch A, Peyton J et al. A phase II trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer. Clin Adv Hematol Oncol 2012;10:430–437.
    1. Ji Y, Du X, Tian Y et al. A phase II study of S‐1 with concurrent radiotherapy in elderly patients with esophageal cancer. Oncotarget 2017;8:83022–83029.
    1. Conroy T, Galais MP, Raoul JL et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): Final results of a randomised, phase 2/3 trial. Lancet Oncol 2014;15:305–314.
    1. Ueda H, Takeda M, Ueda S et al. Clinical evaluation of palliative chemoradiotherapy for metastatic esophageal cancer. Oncotarget 2017;8:80286–80294.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa